Abstract

In a phase I-II study, 28 patients with advanced pancreatic adenocarcinoma were treated with cisplatin, high-dose cytarabine (ARA-C), and caffeine. This clinical trial was based on a nude mouse-human tumor xenograft model, which demonstrated synergism of these agents by inhibiting the growth of human pancreatic tumors. Toxic effects noted in the clinical study included myelosuppression, moderate nausea and vomiting, and mild renal insufficiency. No toxic effects were directly attributable to caffeine. Eighteen of the 28 patients had measurable or assessable disease; seven (39%) had partial responses (95% confidence intervals, 18%-63%). The median response duration was 6.2 months. Median survival for responders was 9.5 months with two patients surviving for more than 18 months. Median survival for all patients was 6.1 months. The combination of cisplatin, ARA-C, and caffeine is an active and tolerable regimen in the treatment of advanced pancreatic cancer. A phase III trial in which this regimen is being compared with standard therapy is in progress.

Keywords

MedicinePancreatic cancerRegimenNauseaVomitingInternal medicineCisplatinGastroenterologyCytarabineChemotherapyPhases of clinical researchOncologyGemcitabineCancer

Affiliated Institutions

Related Publications

Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial

Philip Bonomi , KyungMann Kim , Diane L. Fairclough +5 more

PURPOSE: Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non–small-cell lung cancer (NSCLC). To determine...

2000 Journal of Clinical Oncology 593 citations

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study

Bruno Chauffert , F. Mornex , F. Bonnetain +12 more

The role of chemoradiation with systemic chemotherapy compared with chemotherapy alone in locally advanced pancreatic cancer (LAPC) is uncertain. One hundred and nineteen patien...

2008 Annals of Oncology 681 citations

Publication Info

Year
1989
Type
article
Volume
81
Issue
22
Pages
1735-1738
Citations
28
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

28
OpenAlex

Cite This

James Dougherty, David P. Kelsen, Nancy E. Kemeny et al. (1989). Advanced Pancreatic Cancer: A Phase I-II Trial of Cisplatin, High-Dose Cytarabine, and Caffeine. JNCI Journal of the National Cancer Institute , 81 (22) , 1735-1738. https://doi.org/10.1093/jnci/81.22.1735

Identifiers

DOI
10.1093/jnci/81.22.1735